Mucosal surface ferricyanide reductase activity in mouse duodenum.
Mouse duodenum possesses mucosal surface ferricyanide reductase activity. The reducing activity, determined in vitro by measuring ferrocyanide production from ferricyanide, was found to be greater in duodenal fragments when compared with ileal fragments. Experiments with right-side out tied-off duodenal sacs show that reduction occurs mainly on the mucosal side and indicates that the reducing activity is associated with the brush border membrane. Experiments using mice with increased levels of iron absorption (hypoxic, iron-deficient) showed corresponding increases in reducing activity. The increase was present in duodenal but not ileal fragments. Inhibitor studies showed no effect of several compounds which inhibit other, more characterized, transplasma membrane reductases. In particular, doxorubicin (10 microM) and quinacrine (1mM) were without effect on duodenal mucosal transplasma membrane reducing activity. Depolarization of the membrane potential with high medium K+ inhibited reducing activity. N-ethyl malemide (1 mM) was a potent inhibitor, but iodoacetate was found to be less inhibitory. Comparison with inhibitory effects on glyceraldehyde-3-phosphate dehydrogenase (GAPDH) demonstrated that the effect of N-ethyl malemide on reducing activity was not secondary to GAPDH. Collectively these results indicate that mouse duodenum possesses mucosal surface transplasma membrane ferricyanide reductase activity and that the activity is correlated with the process of intestinal iron absorption. Furthermore, the reducing activity appears to be distinct from other reported transplasma membrane reductases.
Pountney
D J
DJ
Department of Clinical Biochemistry, King's College School of Medicine and Dentistry, London, UK.
Raja
K B
KB
Bottwood
M J
MJ
Wrigglesworth
J M
JM
Simpson
R J
RJ
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004386:Duodenum / Q000187:drug effects / Q000201:enzymology*; D005295:Ferrocyanides / Q000378:metabolism; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism*; D007082:Ileum / Q000187:drug effects / Q000201:enzymology; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure; D007501:Iron / Q000378:metabolism; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D051379:Mice; D008871:Microvilli / Q000187:drug effects / Q000201:enzymology; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010084:Oxidation-Reduction
D005295:Ferrocyanides; D007501:Iron; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D009247:NADH, NADPH Oxidoreductases; C014227:ferricyanide reductase; C020354:hexacyanoferrate II